AZD-6280 is primarily investigated for its potential therapeutic applications in the field of neurology, particularly in the treatment of anxiety disorders. It functions as a GABA-A receptor modulator, which plays a crucial role in regulating neuronal excitability in the brain. By enhancing the activity of GABA, the primary inhibitory neurotransmitter, AZD-6280 helps to reduce excessive neuronal firing, thereby alleviating symptoms associated with anxiety. Its selective action on specific subtypes of GABA-A receptors may offer a favorable side effect profile compared to traditional anxiolytics. Clinical studies have explored its efficacy in managing generalized anxiety disorder (GAD) and other related conditions, aiming to provide a safer and more effective treatment option for patients.